22nd Oct 2020 15:10
(Alliance News) - Verici Dx PLC on Thursday confirmed that it intends to list on London's AIM market, with a total fundraising of GBP14.5 million in its initial public offering.
The company develops clinical tests for organ transplant, which show how well a patient will or is responding to organ transplant - initially focus on kidney transplants.
Verici will issue 72.5 million shares at a price of 20.0 pence each through a placing, subscription and restricted offer. Should the fundraise go through, the company is expected to start trading in London on November 3, with 141.7 million shares issued overall, and a market capitalisation of GBP28.4 million.
Of the shares to be issued, 9.8 million will be converted from loan notes worth USD2.5 million which are held by clinical diagnostics firm Renalytix AI PLC. Verici Dx was formally a subsidiary of Renalytix AI.
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc